Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Nov-Dec;6(6):532-50.
Epub 2015 Nov 1.

Managing Patients With Myelofibrosis in the Era of Janus Kinase Inhibitors

Emily A Knight  1 , Sylvia Osunsuyi-Fagbemi  1 , Jessica Neely  1
Affiliations
Review

Managing Patients With Myelofibrosis in the Era of Janus Kinase Inhibitors

Emily A Knight et al. J Adv Pract Oncol. 2015 Nov-Dec.
No abstract available

PubMed Disclaimer

Figures

Table 1
Table 1
Clinical Manifestations of Myelofibrosis
Table 2
Table 2
Risk Stratification Based on the Dynamic International Prognostic Scoring System Plus
Figure
Figure
Effect of ruxolitinib doses on efficacy
Table 3
Table 3
Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score
Table 4
Table 4
Ruxolitinib Dose Modifications Recommended for MF Patients With a Starting Platelet Count of at Least 100 × 109/La
Table 5
Table 5
Organizations Offering Assistance for Qualifying Patients With Myelofibrosis
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Abdelrahman Ramy A, Begna Kebede H, Al-Kali Aref, Hogan William J, Litzow Mark R, Pardanani Animesh, Tefferi Ayalew. Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis. British journal of haematology. 2015;169:77–80. - PubMed
    1. Babushok Daria, Hexner Elizabeth. Allogeneic transplantation for myelofibrosis: for whom, when, and what are the true benefits? Current opinion in hematology. 2014;21:114–122. - PMC - PubMed
    1. Barbui Tiziano, Barosi Giovanni, Birgegard Gunnar, Cervantes Francisco, Finazzi Guido, Griesshammer Martin, Harrison Claire, Hasselbalch Hans Carl, Hehlmann Rudiger, Hoffman Ronald, Kiladjian Jean-Jacques, Kröger Nicolaus, Mesa Ruben, McMullin Mary F, Pardanani Animesh, Passamonti Francesco, Vannucchi Alessandro M, Reiter Andreas, Silver Richard T, Verstovsek Srdan, Tefferi Ayalew. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29:761–770. - PMC - PubMed
    1. Barosi G, Campanelli R, Fois G, Poletto V, Villani L, Bonetti E, Massa M. Decrease of T regulatory cells in patients with myelofibrosis receiving ruxolitinib [Abstract 4057] Blood (ASH Annual Meeting Abstracts) 2013;122:21.
    1. Barosi G, Mesa R A, Thiele J, Cervantes F, Campbell P J, Verstovsek S, Dupriez B, Levine R L, Passamonti F, Gotlib J, Reilly J T, Vannucchi A M, Hanson C A, Solberg L A, Orazi A, Tefferi A. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008;22:437–438. - PubMed

LinkOut - more resources